Health Economics›Classical Hodgkin lymphoma›Relapsed or refractory all lines of therapy

Relapsed or refractory all lines of therapy

Classical Hodgkin lymphoma · 37 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 7 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
O-ESHAP Variant #01	—	R 1 539 975	28d	—	—	—	—	—
Bendamustine and Brentuximab vedotin Variant #01	—	R 90 663	21d	—	—	—	—	—
Brentuximab vedotin monotherapy Variant #01	—	R 85 244	21d	8.3 mo	—	13	R 1 108 171 PFS proxy	1
Brentuximab vedotin and Nivolumab Variant #01 Partial	—	R 85 244	21d	—	—	—	—	—
Gemcitabine and Rituximab Variant #02	—	R 63 243	28d	—	~9.5 mo	—	—	1
Ifosfamide and Vinorelbine Variant #01	—	R 23 217	21d	—	—	—	—	—
IGEV Variant #01	—	R 19 687	21d	—	—	—	—	—
Everolimus monotherapy Variant #01	—	R 18 360	28d	~6.0 mo	~18.1 mo	~7	~R 128 518 PFS proxy · indirect	15
GCD-R Variant #01	—	R 16 011	21d	—	—	—	—	—
Gemcitabine monotherapy Variant #20	—	R 14 213	56d	~5.2 mo	—	~3	~R 42 639 PFS proxy · indirect	1
GVD Variant #01	—	R 13 431	21d	—	—	—	—	—
ICE Variant #01	—	R 11 539	14d	—	~13.9 mo	—	—	—
BeGEV Variant #01	—	R 7 909	21d	—	—	—	—	—
Lenalidomide monotherapy N/A - secondary systemic drug	—	R 6 361	90d	~8.7 mo	—	~3	~R 19 084 PFS proxy · indirect	3
Bendamustine monotherapy Variant #01	—	R 5 419	—	~16.5 mo	—	—	—	2
GCD Variant #01	—	R 4 215	21d	—	—	—	—	—
DHAP Variant #01	—	R 3 777	28d	—	—	—	—	—
DHAP - time intensified Variant #01	—	R 3 777	—	—	—	—	—	—
ESHAP Variant #01	—	R 3 716	21d	—	—	—	—	—
GVP Variant #01	—	R 3 452	28d	—	—	—	—	—
eBEACOPP (Prednisolone) Variant #01 Partial	—	R 2 970	21d	—	—	—	—	—
eBEACOPP Variant #01 Partial	—	R 2 945	21d	—	—	—	—	2
ABVD Variant #01	—	R 2 916	28d	—	—	—	—	4
DexaBEAM Variant #01 Partial	—	R 2 200	28d	—	—	—	—	—
MINE N/A - secondary systemic drug	—	R 2 064	28d	—	—	—	—	—
BEACOPP-14 (Prednisolone) Variant #01 Partial	—	R 1 685	14d	—	—	—	—	—
BEACOPP Variant #01 Partial	—	R 1 672	21d	—	—	—	—	—
Vinorelbine monotherapy Variant #01	—	R 583	21d	~4.0 mo	~9.4 mo	~6	~R 3 500 PFS proxy · indirect	26
Vinblastine monotherapy Variant #01	—	R 196	14d	—	—	—	—	—
Rituximab monotherapy N/A - secondary systemic drug	—	R 52	180d	~5.2 mo	—	~1	~R 52 PFS proxy · indirect	3
Mini-BEAM N/A - secondary systemic drug	—	R 0	42d	—	—	—	—	—
Penpulimab monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—
Sintilimab monotherapy Variant #01 Partial	—	—	14d	—	~11.8 mo	—	—	1
Zimberelimab monotherapy Variant #01 Partial	—	—	14d	—	—	—	—	—
Tislelizumab monotherapy Variant #01 Partial	—	—	21d	—	~16.0 mo	—	—	3
Nivolumab monotherapy Variant #01 Partial	—	—	14d	~4.6 mo	~12.2 mo	~11	—	28
Camrelizumab monotherapy Variant #01 Partial	—	—	14d	—	~8.0 mo	—	—	1

37 of 37 regimens shown